- call +1-201-465-4211
- email sales@mrinsights.biz
Diagnosis of lung cancer depends on lung histology or sputum shedding cytology. Screening methods for lung cancer mainly include X-ray chest X-ray and sputum cytology, low-dose spiral CT, blood and sputum biomarkers, and exhalation gas monitoring.
Scope of the Report:
As people's awareness of cancer increases and technology advances, as well as private and government support, these are some of the factors that are expected to drive market growth.
The global Lung Cancer Diagnostics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Lung Cancer Diagnostics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Lung Cancer Diagnostics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Lung Cancer Diagnostics market by product type and applications/end industries.
Market Segment by Companies, this report covers
Roche Diagnostics
BioMérieux
Qiagen
Advpharma
AIT Austrian Institute of Technology
Courtagen Life Sciences
DiagnoCure
BioMark Diagnostics
Mayo Clinic
HalioDx SAS
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Immunoassays
Flow Cytometry
Rapid Tests
Molecular Assays
Tissue Arrays
Circulating Tumor Cells
Pharmacodiagnostics
Biomarkers
Other
Market Segment by Applications, can be divided into
Industrial
Healthcare
Other
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Lung Cancer Diagnostics Market Overview
1.1 Product Overview and Scope of Lung Cancer Diagnostics
1.2 Classification of Lung Cancer Diagnostics by Types
1.2.1 Global Lung Cancer Diagnostics Revenue Comparison by Types (2017-2023)
1.2.2 Global Lung Cancer Diagnostics Revenue Market Share by Types in 2017
1.2.3 Immunoassays
1.2.4 Flow Cytometry
1.2.5 Rapid Tests
1.2.6 Molecular Assays
1.2.7 Tissue Arrays
1.2.8 Circulating Tumor Cells
1.2.9 Pharmacodiagnostics
1.2.10 Biomarkers
1.2.11 Other
1.3 Global Lung Cancer Diagnostics Market by Application
1.3.1 Global Lung Cancer Diagnostics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Industrial
1.3.3 Healthcare
1.3.4 Other
1.4 Global Lung Cancer Diagnostics Market by Regions
1.4.1 Global Lung Cancer Diagnostics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Lung Cancer Diagnostics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Lung Cancer Diagnostics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Lung Cancer Diagnostics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Lung Cancer Diagnostics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Lung Cancer Diagnostics Status and Prospect (2013-2023)
1.5 Global Market Size of Lung Cancer Diagnostics (2013-2023)
2 Manufacturers Profiles
2.1 Roche Diagnostics
2.1.1 Business Overview
2.1.2 Lung Cancer Diagnostics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Roche Diagnostics Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.2 BioMérieux
2.2.1 Business Overview
2.2.2 Lung Cancer Diagnostics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 BioMérieux Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Qiagen
2.3.1 Business Overview
2.3.2 Lung Cancer Diagnostics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Qiagen Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Advpharma
2.4.1 Business Overview
2.4.2 Lung Cancer Diagnostics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Advpharma Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.5 AIT Austrian Institute of Technology
2.5.1 Business Overview
2.5.2 Lung Cancer Diagnostics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 AIT Austrian Institute of Technology Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Courtagen Life Sciences
2.6.1 Business Overview
2.6.2 Lung Cancer Diagnostics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Courtagen Life Sciences Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.7 DiagnoCure
2.7.1 Business Overview
2.7.2 Lung Cancer Diagnostics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 DiagnoCure Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.8 BioMark Diagnostics
2.8.1 Business Overview
2.8.2 Lung Cancer Diagnostics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 BioMark Diagnostics Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Mayo Clinic
2.9.1 Business Overview
2.9.2 Lung Cancer Diagnostics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Mayo Clinic Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
2.10 HalioDx SAS
2.10.1 Business Overview
2.10.2 Lung Cancer Diagnostics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 HalioDx SAS Lung Cancer Diagnostics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Lung Cancer Diagnostics Market Competition, by Players
3.1 Global Lung Cancer Diagnostics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Lung Cancer Diagnostics Players Market Share
3.2.2 Top 10 Lung Cancer Diagnostics Players Market Share
3.3 Market Competition Trend
4 Global Lung Cancer Diagnostics Market Size by Regions
4.1 Global Lung Cancer Diagnostics Revenue and Market Share by Regions
4.2 North America Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
4.3 Europe Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
4.5 South America Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
5 North America Lung Cancer Diagnostics Revenue by Countries
5.1 North America Lung Cancer Diagnostics Revenue by Countries (2013-2018)
5.2 USA Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
5.3 Canada Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
5.4 Mexico Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
6 Europe Lung Cancer Diagnostics Revenue by Countries
6.1 Europe Lung Cancer Diagnostics Revenue by Countries (2013-2018)
6.2 Germany Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
6.3 UK Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
6.4 France Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
6.5 Russia Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
6.6 Italy Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Lung Cancer Diagnostics Revenue by Countries
7.1 Asia-Pacific Lung Cancer Diagnostics Revenue by Countries (2013-2018)
7.2 China Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
7.3 Japan Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
7.4 Korea Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
7.5 India Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
8 South America Lung Cancer Diagnostics Revenue by Countries
8.1 South America Lung Cancer Diagnostics Revenue by Countries (2013-2018)
8.2 Brazil Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
8.3 Argentina Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
8.4 Colombia Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Lung Cancer Diagnostics by Countries
9.1 Middle East and Africa Lung Cancer Diagnostics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
9.3 UAE Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
9.4 Egypt Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
9.6 South Africa Lung Cancer Diagnostics Revenue and Growth Rate (2013-2018)
10 Global Lung Cancer Diagnostics Market Segment by Type
10.1 Global Lung Cancer Diagnostics Revenue and Market Share by Type (2013-2018)
10.2 Global Lung Cancer Diagnostics Market Forecast by Type (2018-2023)
10.3 Immunoassays Revenue Growth Rate (2013-2023)
10.4 Flow Cytometry Revenue Growth Rate (2013-2023)
10.5 Rapid Tests Revenue Growth Rate (2013-2023)
10.6 Molecular Assays Revenue Growth Rate (2013-2023)
10.7 Tissue Arrays Revenue Growth Rate (2013-2023)
10.8 Circulating Tumor Cells Revenue Growth Rate (2013-2023)
10.9 Pharmacodiagnostics Revenue Growth Rate (2013-2023)
10.10 Biomarkers Revenue Growth Rate (2013-2023)
10.11 Other Revenue Growth Rate (2013-2023)
11 Global Lung Cancer Diagnostics Market Segment by Application
11.1 Global Lung Cancer Diagnostics Revenue Market Share by Application (2013-2018)
11.2 Lung Cancer Diagnostics Market Forecast by Application (2018-2023)
11.3 Industrial Revenue Growth (2013-2018)
11.4 Healthcare Revenue Growth (2013-2018)
11.5 Other Revenue Growth (2013-2018)
12 Global Lung Cancer Diagnostics Market Size Forecast (2018-2023)
12.1 Global Lung Cancer Diagnostics Market Size Forecast (2018-2023)
12.2 Global Lung Cancer Diagnostics Market Forecast by Regions (2018-2023)
12.3 North America Lung Cancer Diagnostics Revenue Market Forecast (2018-2023)
12.4 Europe Lung Cancer Diagnostics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Lung Cancer Diagnostics Revenue Market Forecast (2018-2023)
12.6 South America Lung Cancer Diagnostics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Lung Cancer Diagnostics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Lung Cancer Diagnostics Picture
Table Product Specifications of Lung Cancer Diagnostics
Table Global Lung Cancer Diagnostics and Revenue (Million USD) Market Split b
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
